Healthcare and life sciences

The 21 October edition, read in full, says patients are uploading results to chatbots and sometimes second-guessing their doctors. The experience is happening whether a health system designs it. The same edition says the research estimates artificial intelligence can take a substantial share of core tasks for almost 60 percent of healthcare workers, which pushes clinicians toward oversight and the cases that still need a person.

Two October notes frame medtech’s problem as customer experience, and as needing more than a market rotation to win investors back. The bodies were not opened. The signal from the subjects is enough to treat CX and the equity story as live, not as a communications afterthought.

The 14 October edition, read in full, reports that people with none of diabetes, high blood pressure, and smoking in midlife lived nearly 13 years longer without dementia than those with all three. The research argument is that most drivers of health — diet, exercise, economic security, environment — sit outside formal healthcare, so governments have to act across sectors. A separate subject headlines a $16.4 trillion healthy-living opportunity, and another tells leaders to prefer evidence over hype. Hold the size as a headline in the mailbox, not as a figure this section has audited.

Novartis is in the inbox on scaling AI beyond the demo. Genentech’s CMO is in it on the marketer as an impact driver. A separate note points AI drug discovery at “what matters most,” and another sketches the biopharma plant as backbones and networks. The pattern is industrializing a proof, not collecting more proofs.